Sentinel Node Biopsy for Nonmelanoma Skin Cancer of the Head and Neck.
Cutaneous squamous cell carcinoma
Merkel cell carcinoma
Sebaceous cell carcinoma
Sentinel lymph node biopsy
Journal
Otolaryngologic clinics of North America
ISSN: 1557-8259
Titre abrégé: Otolaryngol Clin North Am
Pays: United States
ID NLM: 0144042
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
entrez:
21
3
2021
pubmed:
22
3
2021
medline:
26
11
2021
Statut:
ppublish
Résumé
Sentinel lymph node biopsy has the potential to impact regional control and survival for high-risk cutaneous malignancy. The outcome of sentinel lymph node biopsy is a potential guide for treatment and surveillance. The population of high-risk nonmelanoma patients that will benefit from sentinel lymph node biopsy remains to be determined. Any cutaneous malignancy with a greater than 10% risk of occult metastasis should be considered for sentinel lymph node biopsy or active surveillance. Localized cutaneous squamous cell carcinoma lesions with multiple high-risk features and nearly all patients with localized Merkel cell carcinoma should be considered for sentinel lymph node biopsy.
Identifiants
pubmed: 33743888
pii: S0030-6665(20)36751-7
doi: 10.1016/j.otc.2020.11.005
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
295-305Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure R. Sethi – No disclosures. K. Emerick – Consultant; Regeneron and Sanofi; This work does not directly relate to sentinel lymph node biopsy and this content. Work does relate to systemic therapy for cSCC.